Unicycive Therapeutics, Inc.
NASDAQUnicycive Therapeutics heads into the week after a Q1 earnings miss with analysts trimming targets but the stock, paradoxically, holding its ground. The most important development on UNCY right now is the widening gap between analyst caution and the stock's resilience. The company reported Q1 EPS of -$0.54 on May 12, missing the -$0.46 consensus estimate by $0.08. The…
Snapshot as of 28 Jun 2026
Unicycive Therapeutics heads into the week after a Q1 earnings miss with analysts trimming targets but the stock, paradoxically, holding its ground. The most important development on UNCY right now is the widening gap…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for UNCY — free to start on ORTEX.
Sign up for free →Open UNCY on ORTEX